author-photo

Shenghui Tang

Food and Drug Administration

64

Papers

3878

Citations

Citation Trend

Filter By

Papers (48) Sort By

Journal Conference Others

An FDA-pooled analysis of frontline combination treatment benefits by risk groups in metastatic renal cell carcinoma (mRCC).

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (1)
An FDA pooled analysis: Characteristics and outcomes of patients with nonmetastatic castration-resistant prostate cancer, based on prior history of prostatectomy and/or radiation therapy.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
U.S. FDA Drug Approvals for Breast Cancer - A Decade in Review.

2021 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Model Development of CDK4/6 Predicted Efficacy in Patients With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced or Metastatic Breast Cancer.

2021
Show All
- Source
- Cite
- Save
Citations (0)
Outcomes of anti-PD-(L1) therapy in combination with chemotherapy versus immunotherapy (IO) alone for first-line (1L) treatment of advanced non-small cell lung cancer (NSCLC) with PD-L1 score 1-49%: FDA pooled analysis.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (3)
FDA Approval Summary: Tivozanib for Relapsed or Refractory Renal Cell Carcinoma.

2021 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (2)
Overall survival in patients with breast cancer treated with a CDK 4/6 inhibitor plus fulvestrant: A U.S. Food and Drug Administration pooled analysis.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Survival benefit of nephrectomy prior to immunotherapy-based combinations in patients with metastatic renal cell carcinoma: An FDA pooled analysis.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
An FDA analysis of the association of tumor growth rate and overall and progression-free survival in metastatic non-small cell lung cancer (NSCLC) patients.

2020 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (2)
FDA Approval Summary: Lurbinectedin for the Treatment of Metastatic Small Cell Lung Cancer.

2020 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (12)